Darolutamide and survival in nonmetastatic, castration-resistant prostate cancer: a patient perspective of the ARAMIS trial

The latest publication by the Video Journal of Biomedicine summarizes the ARAMIS (Androgen Receptor Antagonizing Agent for Metastasis-free Survival) trial, which was published in the New England Journal of Medicine in September 2020.

The trial was in adult participants with nonmetastatic, castration-resistant prostate cancer who received a trial treatment called darolutamide (brand name Nubeqa®). The summary also includes insights and perspectives from a participant who was in the ARAMIS trial and from a prostate cancer patient advocate.

Original publication:

Fizazi K, Blue I & Nowak JT. Darolutamide and survival in nonmetastatic, castration-resistant prostate cancer: a patient perspective of the ARAMIS trial. doi:10.2217/fon-2020-1291 Future Oncol. (2021).

About the Video Journal of Biomedicine:

The Video Journal of Biomedicine, published by Future Medicine, provides the missing link between high-quality research information and its intended audience, be that fellow experts, researchers in other fields, students and trainees, or the general public (including patients and caregivers). Through concise, high-quality videos, with the author on screen or via voice-over animation, researchers are able to personally explain their work, highlighting its importance, placing it in context, and discussing future implications.

Visit the Video Journal of Biomedicine to find out more>>

The opinions expressed in this interview are those of the interviewee and do not necessarily reflect the views of Oncology Central or Future Science Group.